V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004405 | 10002784 | 1.62 | 53.6 | null | 2018-08-13 | 2018-08-26 | Liposomal Doxorubicin 50mg/m2 | 02 | N | 10522784 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004406 | 10002785 | 1.76 | null | Palliative (P) | 2015-02-07 | 2015-03-04 | IDELALISIB + RITUXIMAB | N | Y | 10522786 | ACELARATE TRIAL |
| 10004407 | 10002786 | 1.63 | null | Disease modification (D) | 2016-08-07 | 2016-08-07 | Capecitabine + Cisplatin + RT | N | null | 10522870 | CARBOPLATIN + RT |
| 10004408 | 10002787 | 1.7 | null | Palliative (P) | 2016-11-01 | 2016-10-25 | Cladribine (subcut) 5 days | 02 | null | 10522880 | NOT MATCHED |
| 10004409 | 10002787 | 1.72 | 58.6 | Palliative (P) | 2016-05-21 | 2016-05-21 | IPILIMUMAB + NIVOLUMAB | N | N | 10522880 | PEMETREXED |
| 10004410 | 10002788 | null | 83 | Palliative (P) | 2013-08-02 | 2013-08-05 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | 10522915 | CHLORAMBUCIL + RITUXIMAB |
| 10004411 | 10002789 | 1.69 | 0 | Palliative (P) | 2018-04-05 | 2018-04-08 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10522937 | CAPECITABINE + MITOMYCIN |
| 10004412 | 10002790 | 1.6 | 51 | Curative (C) | 2015-11-13 | 2015-11-25 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL + Pertuzumab + Trastuzumab | N | N | 10523236 | IBRUTINIB |
| 10004413 | 10002791 | 1.76 | 92.5 | Palliative (P) | 2016-05-17 | 2016-05-29 | Bevacizumab + Cape + Oxali 21day | 01 | N | 10523299 | INCA TRIAL |
| 10004414 | 10002792 | 0 | 104.6 | Curative (C) | 2015-05-05 | 2017-05-04 | BORTEZOMIB + THALIDOMIDE | N | N | 10523369 | PACE-BOM |
| 10004415 | 10002793 | 1.83 | null | null | 2016-09-25 | 2016-10-04 | MPT | null | N | 10523570 | UKALL2014 |
| 10004416 | 10002794 | 0 | 60.9 | Palliative (P) | 2014-10-03 | 2014-10-21 | Bortezomib + MELPHALAN | N | N | 10523576 | VINORELBINE |
| 10004417 | 10002795 | null | null | Curative (C) | 2018-09-03 | 2018-09-17 | FLUOROURACIL + MITOMYCIN | N | N | 10523641 | BORTEZOMIB + THALIDOMIDE |
| 10004418 | 10002796 | 1.6 | 101.5 | Palliative (P) | 2015-06-12 | 2015-06-22 | CETUXIMAB | 2 | N | 10523905 | IPILIMUMAB |
| 10004419 | 10002796 | 1.88 | 70 | Curative (C) | 2016-08-13 | 2016-09-05 | CYCLOPHOSPHAMIDE + RITUXIMAB | null | N | 10523905 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004420 | 10002797 | 1.86 | 67.3 | Curative (C) | null | 2013-11-13 | Bortezomib + MELPHALAN | N | N | 10524074 | MITOMYCIN |
| 10004421 | 10002798 | null | 84.1 | Curative (C) | 2017-11-08 | 2017-11-09 | Bexarotene | 02 | N | 10524099 | RUXOLITINIB |
| 10004422 | 10002798 | 1.71 | 83 | Palliative (P) | 2018-11-29 | 2018-12-12 | ANAGRELIDE | N | N | 10524099 | STAMPEDE TRIAL |
| 10004423 | 10002799 | 1.71 | 0 | Curative (C) | 2018-03-05 | 2018-03-05 | FLAIR Trial | N | N | 10524206 | RUXOLITINIB |
| 10004424 | 10002800 | 1.56 | 65.9 | Palliative (P) | 2014-08-25 | 2014-08-28 | Dacarbazine | N | N | 10524228 | CAPECITABINE + CARBOPLATIN |
| 10004425 | 10002801 | null | 69.5 | null | 2018-03-19 | 2018-03-19 | Trastuzumab Subcutaneous | 02 | N | 10524278 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004426 | 10002802 | null | 83 | Palliative (P) | 2016-03-06 | 2016-03-06 | Pazopanib | 2 | N | 10524321 | VEMURAFENIB |
| 10004427 | 10002803 | 1.54 | 68.6 | Palliative (P) | 2017-10-29 | 2017-10-29 | Capecitabine + Mitomycin | N | N | 10524421 | NILOTINIB |
| 10004428 | 10002803 | 1.76 | 84.2 | Palliative (P) | 2017-04-07 | 2017-04-21 | MITOMYCIN | 2 | Y | 10524421 | RIALTO TRIAL |
| 10004429 | 10002804 | 1.6 | 47.3 | Adjuvant (A) | 2017-04-04 | 2017-04-16 | R-EPOCH | N | N | 10524475 | DOXORUBICIN |
| 10004430 | 10002804 | 1.55 | 67.2 | Curative (C) | 2017-06-05 | 2017-06-08 | RUXOLITINIB | N | N | 10524475 | TAC |
| 10004431 | 10002804 | 1.72 | null | Palliative (P) | 2017-12-11 | 2017-12-19 | Mitomycin Intravesical | 2 | N | 10524475 | CETUXIMAB + RT |
| 10004432 | 10002804 | 1.74 | 70 | Palliative (P) | 2015-08-02 | 2015-08-17 | Ipilimumab | N | N | 10524475 | ECARBOX |
| 10004433 | 10002804 | 1.47 | 43.7 | Palliative (P) | 2015-08-20 | 2015-08-30 | RUXOLITINIB | N | N | 10524475 | DABRAFENIB + TRAMETINIB |
| 10004434 | 10002804 | 1.73 | null | Palliative (P) | 2018-01-19 | 2018-02-14 | IBRUTINIB | 02 | Y | 10524475 | SORAFENIB |
| 10004435 | 10002804 | 1.82 | 108 | Curative (C) | 2018-05-20 | 2018-05-20 | Capecitabine + Cisplatin + RT | 2 | N | 10524475 | GEFITINIB |
| 10004436 | 10002804 | 1.77 | 72.1 | Neo-adjuvant (N) | 2016-07-16 | 2016-08-17 | Cyclophosphamide + Dex + Rituximab | 02 | N | 10524475 | DOXORUBICIN EMBOLISATION |
| 10004437 | 10002805 | null | null | Palliative (P) | 2017-09-15 | 2017-09-15 | MITOMYCIN | N | N | 10525477 | IPILIMUMAB + NIVOLUMAB |
| 10004438 | 10002806 | 0 | null | Palliative (P) | 2015-04-07 | 2015-04-13 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 02 | N | 10525617 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004439 | 10002806 | 1.63 | 70 | Palliative (P) | 2016-05-18 | 2016-05-19 | CHOP R + METHOTREXATE | 02 | N | 10525617 | CETUXIMAB + RT |
| 10004440 | 10002806 | 1.4 | null | Disease modification (D) | 2017-04-17 | 2017-05-08 | Pazopanib | 2 | N | 10525617 | BLEOMYCIN |
| 10004441 | 10002806 | 0 | 0 | Palliative (P) | 2017-11-11 | 2017-11-11 | DA 3 + 10 | N | N | 10525617 | CETUXIMAB + RT |
| 10004442 | 10002807 | 1.82 | 0 | Palliative (P) | 2014-07-27 | 2014-09-24 | Gemcitabine+Paclitaxel (Neo-tAnGo) | 02 | Y | 10526084 | VEMURAFENIB |
| 10004443 | 10002808 | 0 | 0 | Palliative (P) | null | 2017-02-18 | VINCRISTINE | 02 | N | 10526179 | CARBOPLATIN + DOCETAXEL |
| 10004444 | 10002809 | 1.73 | 73.8 | Palliative (P) | 2014-08-19 | 2014-09-21 | Lomustine | 2 | N | 10526243 | CISPLATIN + VINORELBINE + RT |
| 10004445 | 10006643 | null | 59.2 | Palliative (P) | 2017-03-24 | 2017-04-18 | COMPLEMENT TRIAL | null | N | 10526297 | CYTARABINE |
| 10004446 | 10002810 | 1.75 | 91.6 | Palliative (P) | null | 2018-09-17 | Vemurafenib | N | N | 10526505 | CETUXIMAB + IRINOTECAN + MDG |
| 10004447 | 10002811 | 1.82 | null | Palliative (P) | 2013-09-03 | 2013-09-03 | Doxorubicin chemoembolisation | 02 | N | 10526550 | PANITUMUMAB |
| 10004448 | 10008187 | null | 82.3 | Palliative (P) | 2015-09-30 | 2015-10-06 | Bortezomib + MELPHALAN | 02 | N | 10526569 | DACARBAZINE |
| 10004449 | 10002812 | null | 47.1 | Palliative (P) | 2015-03-03 | 2015-03-05 | TEMOZOLOMIDE | N | N | 10526597 | CETUXIMAB + IRINOTECAN + MDG |
| 10004450 | 10006644 | null | 73 | Palliative (P) | 2016-11-24 | 2016-12-04 | Cyclophos + Dex + Lenalidomide | 02 | null | 10526627 | SORAFENIB |
| 10004451 | 10002813 | null | 65.7 | Palliative (P) | 2017-08-03 | 2017-08-04 | VISMODEGIB | 02 | N | 10526752 | ERLOTINIB |
| 10004452 | 10006645 | 1.8 | 0 | null | 2017-12-27 | 2018-01-07 | CETUXIMAB + IRINOTECAN + MDG | null | N | 10526926 | CISPLATIN + FLUOROURACIL |
| 10004453 | 10006645 | 0 | 0 | Palliative (P) | 2016-03-14 | 2016-03-16 | Folfirinox | 2 | N | 10526926 | BREVITY TRIAL |
| 10004454 | 10002814 | 1.75 | 83.4 | Palliative (P) | 2016-10-21 | 2016-10-24 | IDELALISIB | null | N | 10527006 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |